$MOBI

Mobia Medical, Inc.

CIK:0001489993|SEC Filings

Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Condensed Statements of Operations - USD ($) $ in Thousands	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Revenues	$ 13,505	$ 6,674	$ 25,579	$ 12,335
Cost of goods sold	2,267	1,184	4,400	2,199
Gross Profit	11,238	5,490	21,179	10,136
Operating expenses
Research and Development Expense	2,278	1,418	3,970	2,772
Selling, General and Administrative Expense	26,886	14,532	52,072	28,128
Total operating expenses	29,164	15,950	56,042	30,900
Loss from operations	(17,926)	(10,460)	(34,863)	(20,764)
Other income (expense)
Change in fair value of convertible notes payable	(4,142)	0	(4,870)	0
Interest expense	(254)	(241)	(611)	(480)
Other income (expense), net	1,281	213	1,563	104
Total other expense, net	(3,115)	(28)	(3,918)	(376)
Loss before provision for income tax	(21,041)	(10,488)	(38,781)	(21,140)
Provision for income tax	(2)	(2)	(2)	(3)
Net loss attributable to common stockholders	$ (21,043)	$ (10,490)	$ (38,783)	$ (21,143)
Net loss per share attributable to common stockholders
Basic (in dollars per share)	$ (1.1)	$ (12.44)	$ (3.86)	$ (25.41)
Diluted (in dollars per share)	$ (1.1)	$ (12.44)	$ (3.86)	$ (25.41)
Share (denominator):
Weighted average number of common shares outstanding used in basic computation	19,089,211	843,168	10,054,267	832,224
Shares used in diluted computation	19,089,211	843,168	10,054,267	832,224

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities
Net loss	$ (38,783)	$ (21,143)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	191	63
Share-based compensation	2,014	605
Change in fair value of convertible notes payable	4,870	0
Change in fair value of warrant liabilities	(205)	263
Fair value adjustment of redeemable convertible preferred stock tranche liability	0	117
Amortization of debt discount and debt issuance costs	149	18
Changes in operating assets and liabilities
Accounts receivable	(1,229)	(49)
Inventory	(1,493)	(1,076)
Other assets	(997)	104
Accounts payable	540	285
Accrued liabilities and other	1,545	91
Net cash used in operating activities	(33,398)	(20,722)
Cash flows from investing activities
Purchases of property and equipment	(1,582)	(23)
Net cash used in investing activities	(1,582)	(23)
Cash flows from financing activities
Exercise of common stock options	540	222
Proceeds from issuance of common stock in public offering, net	137,501	0
Proceeds from issuance of common stock in warrant exercise	442	0
Proceeds from issuance of convertible notes payable	14,102	0
Proceeds from the related party issuance of convertible notes payable	25,898	0
Proceeds from issuance of Series F redeemable convertible preferred stock, net of issuance costs	0	29,611
Proceeds from the related party issuance of Series F redeemable convertible preferred stock, net of issuance costs	0	2,602
Net cash provided by financing activities	178,483	32,435
Net change in cash and cash equivalents	143,503	11,690
Cash and cash equivalents, beginning of period	33,587	14,620
Cash and cash equivalents, end of period	177,090	26,310
Supplemental disclosures of cash flows information
Cash paid for interest	462	462
Cash paid for taxes	0	2
Unpaid accrued offering costs	$ 3,500	$ 0

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Assets, Current [Abstract]
Cash and cash equivalents	$ 177,090	$ 33,587
Accounts receivable	5,664	4,435
Inventory	6,949	5,457
Deferred offering costs		935
Other current assets	2,446	1,943
Total current assets	192,149	46,357
Property and equipment, net	2,060	669
Right-of-use assets - operating leases	932	1,068
Other assets	143	55
Total assets	195,284	48,149
Current liabilities
Accounts payable	2,359	2,223
Operating lease liabilities, current	358	358
Product warranty liability	1,263	844
Accrued payroll, commissions, and bonuses	4,997	4,854
Accrued offering costs	3,500	935
Accrued and other current liabilities	1,995	992
Total current liabilities	14,472	10,206
Warrant liabilities	134	865
Notes payable, net of discount and deferred financing costs	7,279	7,130
Operating lease liabilities, non-current	790	948
Total liabilities	22,675	19,149
Commitments and contingencies (Note 13)
Redeemable convertible preferred issuable in series, stock, $0.01 par value, zero and 67,174,403 shares authorized as of June 30, 2026 and December 31, 2025, respectively; zero and 65,591,701 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively; aggregate liquidation value of $0 and 182,255 as of June 30, 2026 and December 31, 2025, respectively		179,773
Stockholders' equity (deficit)
Common stock, $0.01 par value, 950,000,000 and 86,600,000 shares authorized as of June 30, 2026 and December 31, 2025, respectively; 33,286,108 and 884,030 shares outstanding as of June 30, 2026 and December 31, 2025, respectively	333	9
Additional paid-in capital	368,848	7,007
Accumulated deficit	(196,572)	(157,789)
Total stockholders' equity (deficit)	172,609	(150,773)
Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit)	$ 195,284	$ 48,149